Article Page-all the options

“There is a massive childhood cancer challenge in Africa. To put it in perspective; in the U.S. there are 15,000 childhood cancers annually and around 80% survive 01. In Sub-Saharan Africa there are 100,000 childhood cancers annually and 90% die 02. Global HOPE was developed to address the inequity and this unacceptable situation.” Dr David G Poplack, Director of Global Hematology Oncology Paediatric Excellence (HOPE).

Dr David G Poplack is internationally recognized as a leader in the field of paediatric oncology who launched Global HOPE in 2016 from Texas Children’s Hospital, the largest children’s hospital in the US. The program has had a life-changing impact in reducing child cancer deaths in Sub-Saharan Africa and its vital partnership with Teva is helping to get medicines where they are needed.

 
Teva has long worked to provide solutions for vulnerable populations who do not have the means or the access to reasonable levels of healthcare and medicine. In 2020, Teva donated $571 million worth of medicines (317 million units) to patients in need, more than double our 2019 donations.

And our ambition is growing. In our 2021 Environmental Social Governance (ESG) Report, we announced goals to increase access to our medicines, which are integrated into our corporate strategy, with certain critical targets linked to executive compensation. 

The Global HOPE program has taken a three-pronged approach

1. Building capacity by training doctors, nurses and health care professionals (HCPs)
2. Enhancing access to essential medicines
3. Improving paediatric healthcare facilities

To date, Global HOPE has treated more than 8,700 patients, trained 3,500 HCPs and is expanding into new countries with their training programs.

“We started in Botswana, Malawi and Uganda, but are training people from many different places in these sites and they are returning to their own countries and setting up pediatric oncology departments there.”

The Teva partnership came about when Dr Poplack discovered that Teva provides 70% of the medicines that are needed to provide support for children with cancer. A meeting at the UN General Assembly on NCDs in 2018 was effective in starting the relationship. Dr Poplack says:

“I’ve seen a lot in terms of pediatric cancer over many years but of all the things I’ve been involved in throughout my career, Global HOPE and this partnership with Teva has the greatest potential medical impact of anything I’ve ever done. There is much we can do together to save many thousands of lives.”

---

Image with captions block

---

Image with captions block: Circular

Captions Placement: Next/ Below the Image or without captions
Optional background colors: Green, Gradient, White, Neutral
Image Type: Circular | Image size: small, 600x600
Fields Captions Title/ Captions Text are optional
**Please note, when using this component with captions next to image as presentng below, make sure to enter up to 300 characters in total (title & text)

Image with captions block

Captions Placement: Below the Image
Optional background colors: Green, Gradient, White, Neutral
Image Type: Circular | Image size: small, 600x600
Fields Captions Title/ Captions Text are optional

As the world continues to grapple with the challenges of the pandemic, the need for cutting-edge, effective treatments and therapies across numerous health conditions is clear. It is likely that this need for preventative, diagnostic, and medical therapies will only continue to grow. Teva, global leader in generics and biopharmaceuticals, aims to meet this challenge by collaborating with top universities and research institutes to identify new medicines.

As the world continues to grapple with the challenges of the pandemic, the need for cutting-edge, effective treatments and therapies across numerous health conditions is clear. It is likely that this need for preventative, diagnostic, and medical therapies will only continue to grow. Teva, global leader in generics and biopharmaceuticals, aims to meet this challenge by collaborating with top universities and research institutes to identify new medicines that will transform healthcare systems and improve the lives of patients.

As the world continues to grapple with the challenges of the pandemic, the need for cutting-edge, effective treatments and therapies across numerous health conditions is clear. It is likely that this need for preventative, diagnostic, and medical therapies will only continue to grow. Teva, global leader in generics and biopharmaceuticals, aims to meet this challenge by collaborating with top universities and research institutes to identify new medicines that will transform healthcare systems and improve the lives of patients.

As the world continues to grapple with the challenges of the pandemic, the need for cutting-edge, effective treatments and therapies across numerous health conditions is clear. It is likely that this need for preventative, diagnostic, and medical therapies will only continue to grow. Teva, global leader in generics and biopharmaceuticals, aims to meet this challenge by collaborating with top universities and research institutes to identify new medicines that will transform healthcare systems and improve the lives of patients.

As the world continues to grapple with the challenges of the pandemic, the need for cutting-edge, effective treatments and therapies across numerous health conditions is clear. It is likely that this need for preventative, diagnostic, and medical therapies will only continue to grow. Teva, global leader in generics and biopharmaceuticals, aims to meet this challenge by collaborating with top universities and research institutes to identify new medicines that will transform healthcare systems and improve the lives of patients.As the world continues to grapple with the challenges of the pandemic, the need for cutting-edge, effective treatments and therapies across numerous health conditions is clear. It is likely that this need for preventative, diagnostic, and medical therapies will only continue to grow. Teva, global leader in generics and biopharmaceuticals, aims to meet this challenge by collaborating with top universities and research institutes to identify new medicines that will transform healthcare systems and improve the lives of patients.

Image with captions block, Image Type: Circular | Image size: Small, 600x600 | without using captions | Image Position: Small/ Right

As the worldcontinues to grapple with the challenges of the pandemic, the need for cutting-edge, effective treatments and therapies across numerous health conditions is clear. It is likely that this need for preventative, diagnostic, and medical therapies will only continue to grow. Teva, global leader in generics and biopharmaceuticals, aims to meet this challenge by collaborating with top universities and research institutes to identify new medicines that will transform healthcare systems and improve the lives of patients.

As the world continues to grapple with the challenges of the pandemic, the need for cutting-edge, effective treatments and therapies across numerous health conditions is clear. It is likely that this need for preventative, diagnostic, and medical therapies will only continue to grow. Teva, global leader in generics and biopharmaceuticals, aims to meet this challenge by collaborating with top universities and research institutes to identify new medicines that will transform healthcare systems and improve the lives of patients.

    

---

Image with captions block - Moment

Captions Placement: Next/ Below the Image or without captions
Optional background colors: No background color can be choosen
Image Type: Circular | Image size: small, 600x600
Moment Image View Type: VisualBottomRight, VisualTopRight, BottomRight, TopRight
Fields Captions Title/ Captions Text are optional

 

After more than a year of mapping the academic and research landscape, Teva found immense scientific merit and strength in the Israeli academic ecosystem. In a joint academia-industry effort, Teva already has some 30 projects underway. The Hebrew University of Jerusalem, Tel Aviv University (TAU), the Technion (Israel Institute of Technology), and the Weizmann Institute are among the universities and research institutes participating in these projects.

"We always operate out of a commitment to promote innovation where we can create value for our patients, our partners in the healthcare system, and the rest of our stakeholders," says Kåre Schultz, CEO of Teva. "We are in constant search for original and better ways to develop solutions which strive to answer our patients' unmet needs."

"We always operate out of a commitment to promote innovation where we can create value for our patients, our partners in the healthcare system, and the rest of our stakeholders," says Kåre Schultz, CEO of Teva. "We are in constant search for original and better ways to develop solutions which strive to answer our patients' unmet needs."

 

Image with captions block: Rectangular

Captions Placement: Next/ Below the Image or without captions
Optional background colors: Green, Gradient, White, Neutral
Image Type: Rectangular| Image size: small, 300x225 OR large, 900x676
Fields Captions Title/ Captions Text are optional

**Please note the amount of text is entered into this component, otherwise the text slides beyond the borders of the image

Teva selected these academic institutions for the joint development of innovative and biological drugs in fields such as oncology, immunotherapy, the central nervous system, and respiratory.

It’s a process through which scientific ideas are translated into medically applicable inventions and solutions. We believe there is great potential in developing academic thinking into real-life medical solutions, particularly these days.” 

In the past, collaborations between Teva and Israeli academia have led to breakthrough drugs and treatments that have significantly improved patient care in MS, Parkinson's Disease, and more. Working with Teva's experienced experts, these collaborations are essential for young researchers and contribute to a cross-pollination of ideas that may lead to ground-breaking discoveries.

It’s a process through which scientific ideas are translated into medically applicable inventions and solutions. We believe there is great potential in developing academic thinking into real-life medical solutions, particularly these days.” 

In the past, collaborations between Teva and Israeli academia have led to breakthrough drugs and treatments that have significantly improved patient care in MS, Parkinson's Disease, and more. Working with Teva's experienced experts, these collaborations are essential for young researchers and contribute to a cross-pollination of ideas that may lead to ground-breaking discoveries. 

It’s a process through which scientific ideas are translated into medically applicable inventions and solutions. We believe there is great potential in developing academic thinking into real-life medical solutions, particularly these days.” 

In the past, collaborations between Teva and Israeli academia have led to breakthrough drugs and treatments that have significantly improved patient care in MS, Parkinson's Disease, and more. 

The project is part of the Innovative Medicines Initiative – a public private partnership between the European Union and the European pharmaceutical industry to improve health by speeding up the development of innovative medicines.

“The goal is to connect digital mobility tech with clinical outcomes

“We are using AI and analytics to try to predict and assess the motor stage of the patients' disease, which affects the body’s movement,” says Michal. “And to identify the walking factors most associated with Parkinson's disease motor stages.”

Analysis of our AI models outcomes show that the walking factors' discriminative power vary according to the disease progression: in the early, mild and advanced phases, the important walking factors are measured from the wrists, lower back, and ankles, respectively. This supports the clinical impression of Parkinson's disease progression. “One benefit of this wearable tech is that you monitor the progression of Parkinson’s disease at the patients' home,” Michal adds.

---

Footnotes

1. Back to contents.

   https://www.cancer.gov/types/childhood-cancers/child-adolescent-cancers-fact-sheet#what-is-the-outlook-for-children-and-adolescents-with-cancer-nbsp

2. Back to contents.

   https://ncdalliance.org/sites/default/files/resource_files/20110627_A_Focus_on_Children_&_NCDs_FINAL_2.pdf